Zealand 2025 CMD and Partnership for Obesity Drug Discovery; Lilly Shares Topline Retatrutide Results; Corbus Topline CB1 Data; Dexcom Launches G7 15 Day CGM; Prolynx Series A Funding and Names CEO
A series of cardiometabolic-related news items has been observed from Zealand Pharma, Lilly, Corbus Pharmaceuticals, Dexcom, and Prolynx. Below, FENIX provides highlights and insights for the respective new items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.